🇺🇸 FDA
Pipeline program

Allo-depleted lymphocyte infusion

ALODEPLETE

Phase 1 other terminated

Quick answer

Allo-depleted lymphocyte infusion for Transplant-Related Hematologic Malignancy is a Phase 1 program (other) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Transplant-Related Hematologic Malignancy
Phase
Phase 1
Modality
other
Status
terminated

Clinical trials